Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mepolizumab in COPD With Eosinophilic Bronchitis: A Randomized Clinical Trial
Brief Summary: Some patients with chronic obstructive pulmonary diseases (COPD) have large number of specific white blood cells called eosinophils in their airways. These cells are also responsible for causing episodes of worsened respiratory symptoms (exacerbations) and often cause irreversible damage to the airways . This subset of COPD patients often require oral steroids to bring down the number of eosinophils in their airways. Steroids have harmful effects on several of our body systems like bones, blood pressure, blood glucose control and can cause recurrent infections. Mepolizumab is a drug that specifically targets eosinophils reducing the number in the airway. This drug has been shown to be effective in decreasing exacerbation rates and time to exacerbation in asthma patients with eosinophils in their airways. Targeting eosinophils in COPD patients has been shown to reduce severe exacerbations. Hence it is likely that COPD patients with eosinophils in their airways will benefit similarly and have reduced rates and time to exacerbation.

Study Hypothesis:Does mepolizumab decrease sputum eosinophils in patients with fixed airflow obstruction (COPD) and eosinophilic bronchitis?


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Mepolizumab | Arm Label: Arm 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mepolizumab; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 2
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Mepolizumab | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Mepolizumab | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mepolizumab; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 3
C: Arm Label: mepolizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mepolizumab | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mepolizumab; Assigned to Arm(s): mepolizumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Eosinophilic phenotype (EOS+) Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: EOS+ Benralizumab (2 mg); Type: EXPERIMENTAL; Interventions: Biological: Benralizumab 2 mg | Arm Label: EOS+ Benralizumab (20 mg); Type: EXPERIMENTAL; Interventions: Biological: Benralizumab 20 mg | Arm Label: EOS+ Benralizumab (100 mg); Type: EXPERIMENTAL; Interventions: Biological: Benralizumab 100 mg | Arm Label: Non-eosinophil phenotype (EOS-) Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: EOS- Benralizumab (100 mg); Type: EXPERIMENTAL; Interventions: Biological: Benralizumab 100 mg | Intervention Type: BIOLOGICAL; Name: Benralizumab 2 mg; Assigned to Arm(s): EOS+ Benralizumab (2 mg) | Intervention Type: BIOLOGICAL; Name: Benralizumab 20 mg; Assigned to Arm(s): EOS+ Benralizumab (20 mg) | Intervention Type: BIOLOGICAL; Name: Benralizumab 100 mg; Assigned to Arm(s): EOS+ Benralizumab (100 mg), EOS- Benralizumab (100 mg) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Eosinophilic phenotype (EOS+) Placebo, Non-eosinophil phenotype (EOS-) Placebo

Answer: C